Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    83,217.55
    -3,293.96 (-3.81%)
     

  • CMC Crypto 200

    1,257.04
    -100.97 (-7.44%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

Strength Seen in Chimerix (CMRX): Stock Soars 18.2%

Zacks Equity Research

Chimerix, Inc. (CMRX) was a big mover last session, as the company saw its shares rise over 18% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock jumped after the company received the U.S. Food and Drug Administration’s nod to pre-pone the test of one of its drugs for the treatment of weakened immune system. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $18.73 to $20.60 in the past one-month time frame.

The company has seen one negative and one positive estimate revision in the past 30 days, while its Zacks Consensus Estimate moved lower over the same time frame, suggesting trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Chimerix currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked medical stocks include Enzymotec Ltd. (ENZY), Covidien plc (COV) and Stryker Corporation (SYK). While Enzymo tec spo rts a Zacks Rank #1 (Strong Buy), Covidien and Stryker have a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


CHIMERIX INC (CMRX): Free Stock Analysis Report

ENZYMOTEC LTD ORD (ENZY): Free Stock Analysis Report

(COV): Free Stock Analysis Report

STRYKER CORP (SYK): Free Stock Analysis Report


Zacks Investment Research